Edition:
United States

AB Science SA (ABS.PA)

ABS.PA on Paris Stock Exchange

8.35EUR
20 Sep 2017
Change (% chg)

€0.35 (+4.38%)
Prev Close
€8.00
Open
€8.05
Day's High
€8.44
Day's Low
€7.96
Volume
95,784
Avg. Vol
186,946
52-wk High
€18.07
52-wk Low
€7.53

Chart for

About

AB Science SA, also known as AB Science, is a France-based pharmaceutical company specialized in the research, discovery, development and marketing of protein kinase inhibitors (PKIs). It is engaged in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical factor in the field of cancer,... (more)

Overall

Beta: 1.79
Market Cap(Mil.): €326.32
Shares Outstanding(Mil.): 40.79
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.87 16.18
EPS (TTM): -- -- --
ROI: -- 15.15 14.60
ROE: -- 16.38 13.87

BRIEF-AB Science: CHMP adopts negative opinion for Masitinib marketing authorization

* REG-AB SCIENCE ANNOUNCES THAT CHMP ADOPTED A NEGATIVE OPINION FOR MASITINIB MARKETING AUTHORIZATION IN INDOLENT SYSTEMIC MASTOCYTOSIS AFTER REASSESSMENT

Sep 14 2017

BRIEF-AB Science net loss narrows to 13.5 million euros

* NET LOSS OF 13.5MEUR IN FIRST HALF OF 2017, A DECREASE OF 8.4% AS COMPARED WITH FIRST HALF OF 2016 (14.7MEUR )

Aug 31 2017

BRIEF-AB Science announces issuance of a new european patent

* REG-AB SCIENCE ANNOUNCES ISSUANCE OF A NEW EUROPEAN PATENT FOR PROTECTING THE USE OF MASITINIB IN PANCREATIC CANCER PATIENTS

Jul 12 2017

BRIEF-AB Science presents supportive data from its phase 3 study in severe systemic mastocytosis

* PRESENTS SUPPORTIVE DATA FROM ITS PHASE 3 STUDY IN SEVERE SYSTEMIC MASTOCYTOSIS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jun 22 2017

BRIEF-EU Medicines Agency recommends against approval of AB Science mastocytosis drug Masitinib

* EU Medicines Agency recommends approval of Valeant Pharmaceuticals Inc psoriasis drug Brodalumab

May 19 2017

BRIEF-AB Science presents Phase 3 data for Masitinib in amyotrophic lateral sclerosis (ALS)

* PRESENTS PHASE 3 DATA FOR MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS (ALS)

May 18 2017

BRIEF-Ab Science: CHMP adoptes negative opinion for masitinib in indolent systemic mastocytosis

* REG-AB SCIENCE ANNOUNCES THAT CHMP HAS ADOPTED A NEGATIVE OPINION FOR MASITINIB IN INDOLENT SYSTEMIC MASTOCYTOSIS, PRIMARILY DUE TO GCP INSPECTION FINDINGS

May 17 2017

BRIEF-Trading resumption on shares of AB Science

* Announced today that trading on ordinary shares issued by AB Science will resume on Euronext Paris as of May 16, 2017 at 0900 CET Further company coverage: (Gdynia Newsroom)

May 15 2017

BRIEF-AB Science - ANSM requested temporary suspension of masitinib studies

* Notification from ANSM requesting temporary suspension of ongoing masitinib studies until compliance is confirmed by an external audit

May 11 2017

BRIEF-AB Science FY net loss widens to 27.7 million euros

* Reported on Monday FY net revenues of 1.5 million euros ($1.64 million) versus 2.3 million euros a year ago

May 02 2017

Earnings vs. Estimates